NR 566 Comprehensive Pharmacology
Assessment — Exam Questions with Correct
Answers (VerifiedAnswers) Plus Rationales
2026 Q&A Instant Download PDF
1. A patient taking a highly protein-bound medication develops
hypoalbuminemia. Which pharmacokinetic change is most
likely?
A. Decreased free-drug concentration
B. Increased renal clearance
C. Increased free-drug concentration
D. Decreased drug absorption
Rationale: Albumin binds many medications in the bloodstream.
When albumin levels fall, fewer binding sites are available,
increasing the unbound or free fraction of a highly protein-
bound medication. Because free drug is pharmacologically
active, this can intensify drug effects and increase toxicity risk.
The clinician should consider the patient's albumin level when
evaluating medications with a narrow therapeutic index.
,2. A medication has a half-life of 24 hours. Approximately how
long will it take to reach steady-state concentrations with
repeated dosing?
A. 24 hours
B. 48 hours
C. 72 hours
D. 4–5 days
Rationale: Most medications approach steady state after
approximately four to five half-lives. A medication with a 24-
hour half-life therefore generally requires about four to five
days to reach near-steady-state concentrations. This principle is
important when determining when a therapeutic response or
serum drug concentration can be reliably evaluated.
3. Which pharmacokinetic process describes the movement of a
drug from the gastrointestinal tract into systemic circulation?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Rationale: Absorption is the movement of a medication from its
site of administration into the bloodstream. Distribution occurs
after the drug reaches systemic circulation and describes
,movement into tissues. Metabolism chemically modifies the
drug, primarily in the liver, while excretion removes drug and
metabolites from the body, most commonly through the
kidneys.
4. Which medication characteristic is most concerning when
prescribing for a patient with significantly reduced renal
function?
A. High oral bioavailability
B. Predominantly renal elimination
C. Extensive intestinal absorption
D. Low protein binding
Rationale: Drugs primarily eliminated through the kidneys can
accumulate when renal function is impaired. Accumulation may
increase drug exposure and adverse effects. Depending on the
medication, the prescriber may need to reduce the dose, extend
the dosing interval, or select another medication. Renal function
should therefore be considered before prescribing and during
treatment.
5. Which statement best describes a competitive antagonist?
A. It produces the same maximal effect as an agonist.
B. It permanently destroys the receptor.
, C. It competes with an agonist for the same receptor site.
D. It increases receptor sensitivity regardless of drug
concentration.
Rationale: A competitive antagonist reversibly competes with an
agonist at the same receptor site. Increasing the concentration
of the agonist can overcome the antagonistic effect in many
situations. This differs from an irreversible antagonist, which
produces persistent receptor blockade that cannot simply be
overcome by increasing agonist concentration.
6. A patient taking an ACE inhibitor develops a persistent dry
cough. Which mechanism best explains this adverse effect?
A. Increased dopamine release
B. Reduced aldosterone secretion
C. Increased sodium absorption
D. Accumulation of bradykinin
Rationale: ACE inhibitors block angiotensin-converting enzyme,
which also participates in the breakdown of bradykinin.
Increased bradykinin can contribute to vasodilation but is also
associated with the characteristic persistent dry cough seen
with ACE inhibitors. Patients with troublesome cough may be
considered for an alternative such as an ARB when clinically
appropriate.
Assessment — Exam Questions with Correct
Answers (VerifiedAnswers) Plus Rationales
2026 Q&A Instant Download PDF
1. A patient taking a highly protein-bound medication develops
hypoalbuminemia. Which pharmacokinetic change is most
likely?
A. Decreased free-drug concentration
B. Increased renal clearance
C. Increased free-drug concentration
D. Decreased drug absorption
Rationale: Albumin binds many medications in the bloodstream.
When albumin levels fall, fewer binding sites are available,
increasing the unbound or free fraction of a highly protein-
bound medication. Because free drug is pharmacologically
active, this can intensify drug effects and increase toxicity risk.
The clinician should consider the patient's albumin level when
evaluating medications with a narrow therapeutic index.
,2. A medication has a half-life of 24 hours. Approximately how
long will it take to reach steady-state concentrations with
repeated dosing?
A. 24 hours
B. 48 hours
C. 72 hours
D. 4–5 days
Rationale: Most medications approach steady state after
approximately four to five half-lives. A medication with a 24-
hour half-life therefore generally requires about four to five
days to reach near-steady-state concentrations. This principle is
important when determining when a therapeutic response or
serum drug concentration can be reliably evaluated.
3. Which pharmacokinetic process describes the movement of a
drug from the gastrointestinal tract into systemic circulation?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Rationale: Absorption is the movement of a medication from its
site of administration into the bloodstream. Distribution occurs
after the drug reaches systemic circulation and describes
,movement into tissues. Metabolism chemically modifies the
drug, primarily in the liver, while excretion removes drug and
metabolites from the body, most commonly through the
kidneys.
4. Which medication characteristic is most concerning when
prescribing for a patient with significantly reduced renal
function?
A. High oral bioavailability
B. Predominantly renal elimination
C. Extensive intestinal absorption
D. Low protein binding
Rationale: Drugs primarily eliminated through the kidneys can
accumulate when renal function is impaired. Accumulation may
increase drug exposure and adverse effects. Depending on the
medication, the prescriber may need to reduce the dose, extend
the dosing interval, or select another medication. Renal function
should therefore be considered before prescribing and during
treatment.
5. Which statement best describes a competitive antagonist?
A. It produces the same maximal effect as an agonist.
B. It permanently destroys the receptor.
, C. It competes with an agonist for the same receptor site.
D. It increases receptor sensitivity regardless of drug
concentration.
Rationale: A competitive antagonist reversibly competes with an
agonist at the same receptor site. Increasing the concentration
of the agonist can overcome the antagonistic effect in many
situations. This differs from an irreversible antagonist, which
produces persistent receptor blockade that cannot simply be
overcome by increasing agonist concentration.
6. A patient taking an ACE inhibitor develops a persistent dry
cough. Which mechanism best explains this adverse effect?
A. Increased dopamine release
B. Reduced aldosterone secretion
C. Increased sodium absorption
D. Accumulation of bradykinin
Rationale: ACE inhibitors block angiotensin-converting enzyme,
which also participates in the breakdown of bradykinin.
Increased bradykinin can contribute to vasodilation but is also
associated with the characteristic persistent dry cough seen
with ACE inhibitors. Patients with troublesome cough may be
considered for an alternative such as an ARB when clinically
appropriate.
